all the information, none of the junk | biotech • healthcare • life sciences

Alnylam’s Ebola Work Gets $7.5 Million Commitment

Alnylam Pharmaceuticals (NASDAQ: ALNY) said today that the National Institutes of Health has committed $7.5 million to continue funding another year of its program to develop RNA interference technology against hemorrhagic fever virus, including the deadly Ebola virus. The Cambridge, MA-based company originally got the contract in September 2006, and has received $14.2 million for work over the first two years. The company’s experimental treatment, which uses a lipid-particle delivery method, has been shown to decrease Ebola virus in infected mice, the company said.